Western New England Maternal Pediatric Adolescent AIDS Clinical Trials Unit

描述（由申请人提供）： 为“西部新英格兰孕产妇儿童青少年艾滋病临床试验单位（WNE-MPAACTU）”提供资金的提案是为了响应RFA-AI-05-002而提交的。WNE-MPAACTU是一个临床研究中心联盟，由位于马萨诸塞州伍斯特市的马萨诸塞州大学医学院的主要单位、位于马萨诸塞州斯普林菲尔德市的Baystate医学中心和位于康涅狄格州哈特福德市的康涅狄格州儿童医学中心的临床试验中心组成。自1990年以来，联盟研究人员一直在共同努力，以确定母婴HIV-1传播（MTCT）和儿科HIV-1感染的发病机制，并在设计和实施基于发病机制的临床试验方面经验丰富。WNE-MPAACTU的目标是：1）提高我们对母婴传播和儿童HIV-1感染发病机制的认识; 2）改善儿童和青少年HIV-1感染的预防策略，包括开发有效的预防疫苗; 3）改善儿童和青少年HIV-1感染的治疗策略，包括合并症和ART毒性的管理。这些目标与国际妇幼青少年临床试验（IMPAACT）网络的目标最为一致，该网络将开展疫苗、转化研究/药物开发、临床护理优化和预防MFCT研究。根据过去的业绩和预计的应计利润，WNE-PACTU被选为IMPAACT“高度优先的核心站点”。WNE-MPAACTU研究人员在IMPAACT的发展中发挥了领导作用，并将继续通过领导，培训和指导以及方案设计，实施和应计为IMPAACT科学议程做出贡献。 行政部门：

DESCRIPTION (provided by applicant): This proposal to fund the "Western New England Maternal Pediatric Adolescent AIDS Clinical Trials Unit (WNE-MPAACTU)" is submitted in response to RFA-AI-05-002. The WNE-MPAACTU is a consortium of clinical sites consisting of a main unit at the University of Massachusetts Medical School in Worcester, MA, and Clinical Trials Sites at Baystate Medical Center in Springfield, MA and Connecticut Children's Medical Center in Hartford, CT. Consortium investigators have worked together since 1990 to define the pathogenesis of mother-to-child HIV-1 transmission (MTCT) and pediatric HIV-1 infection and are highly experienced in the design and implementation of pathogenesis-based clinical trials. WNE-MPAACTU goals are: 1) To improve our understanding of the pathogenesis of MTCT and pediatric HIV-1 infection; 2) To improve prevention strategies for pediatric and adolescent HIV-1 infection, including the development of an effective preventive vaccine; and 3) To improve treatment strategies for pediatric and adolescent HIV-1 infection, including the management of co-morbidities and ART toxicities. These goals are most aligned with the goals of the International Maternal Pediatric Adolescent Clinical Trials (IMPAACT) network, which will conduct Vaccine, Translational Research/Drug Development, Optimization of Clinical Care, and Prevention of MFCT studies. Based on past performance and projected accruals, WNE-PACTU has been selected as an IMPAACT "highly-preferred core site". WNE-MPAACTU investigators have played leadership roles in IMPAACT's development and will continue to contribute to the IMPAACT scientific agenda through leadership, training and mentorship, and protocol design, implementation, and accrual. ADMINISTRATIVE COMPONENT: